Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Expeditors International of Wshngtn Inc (EXPD) vs Sana Biotechnology Inc (SANA) Price & Performance

Expeditors International of Wshngtn IncTrade
Sana Biotechnology IncTrade

Price performance (Past 24H)

Key statistics

Expeditors International of Wshngtn Inc vs Sana Biotechnology Inc — how do they compare? Expeditors International of Wshngtn Inc trades at $181.03 (market cap $23.24B), while Sana Biotechnology Inc trades at $3.32 (market cap $987.94M). The key difference: Expeditors International of Wshngtn Inc is far larger — about 23.5× Sana Biotechnology Inc's market cap, and Expeditors International of Wshngtn Inc pays a 0.91% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.

EXPDSANA
Market Cap
$23.24B$987.94M
Sector
IndustrialsHealth
52-Week High
$178.22$5.92
52-Week Low
$111.37$2.68
Enterprise Value
$22.49B$962.13M
Dividend Yield
0.91%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Expeditors International of Wshngtn Inc

Expeditors International (EXPD) trades at $178.22, up 1.55% on the day, and has consistently beaten earnings estimates in recent quarters. The stock shows strong technical momentum with a bullish moving average signal, though oscillators suggest overbought conditions. Fundamentally, the company maintains robust profitability with a 7.48% net margin and 36.59% ROE, supported by positive operating cash flow of $1.01B in 2025. Recent news highlights the stock's inclusion on strong buy lists and its resilience in the transportation services sector.

The outlook is mixed with strong fundamentals and positive earnings momentum offset by a cautious analyst consensus and elevated valuation multiples. The primary opportunity lies in continued execution and e-commerce demand driving intermodal services, while risks include industry freight downturns, economic uncertainties, and the stock trading above the consensus price target of $161.50.

Sana Biotechnology Inc

SANA Biotechnology trades at $3.45, down 3.36% today, with a bullish technical signal from moving averages and oscillators. The company shows strong analyst support with 82% buy ratings but faces significant financial challenges including negative ROE of -147.41% and consistent quarterly losses. Recent developments include positive clinical data presentations and a strategic collaboration with Mayo Clinic announced in May 2026.

While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial cash burn and negative profitability present significant investment risks. The stock's outlook depends heavily on successful clinical development and future revenue generation from its engineered cell therapies.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Expeditors International of Wshngtn Inc

Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.

Read more on EXPD

About Sana Biotechnology Inc

Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.

Read more on SANA